8.00
price up icon3.43%   0.265
after-market After Hours: 8.00
loading
Xencor Inc stock is traded at $8.00, with a volume of 1.34M. It is up +3.43% in the last 24 hours and down -24.39% over the past month. Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$7.735
Open:
$7.63
24h Volume:
1.34M
Relative Volume:
1.45
Market Cap:
$569.36M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-2.7682
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
+5.68%
1M Performance:
-24.39%
6M Performance:
-68.75%
1Y Performance:
-66.51%
1-Day Range:
Value
$7.34
$8.055
1-Week Range:
Value
$7.34
$8.055
52-Week Range:
Value
$7.16
$27.24

Xencor Inc Stock (XNCR) Company Profile

Name
Name
Xencor Inc
Name
Phone
626-305-5900
Name
Address
465 N. HALSTEAD ST., PASADENA, CA
Name
Employee
250
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
XNCR's Discussions on Twitter

Compare XNCR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
XNCR
Xencor Inc
8.00 538.76M 133.62M -177.37M 23.50M -2.89
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Xencor Inc Stock (XNCR) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-21-25 Initiated William Blair Outperform
Dec-12-24 Initiated Wells Fargo Overweight
Dec-02-24 Upgrade Piper Sandler Neutral → Overweight
Apr-16-24 Reiterated BTIG Research Buy
Feb-28-24 Downgrade Piper Sandler Overweight → Neutral
May-19-23 Initiated BofA Securities Buy
Dec-06-22 Initiated Cowen Outperform
Oct-13-22 Upgrade Raymond James Outperform → Strong Buy
Sep-21-22 Initiated JP Morgan Overweight
Jul-06-22 Resumed Canaccord Genuity Buy
Feb-11-22 Initiated BMO Capital Markets Outperform
Jan-21-22 Initiated SMBC Nikko Outperform
Dec-15-21 Initiated H.C. Wainwright Buy
Oct-15-21 Resumed BTIG Research Buy
Feb-24-21 Upgrade Raymond James Mkt Perform → Outperform
Mar-04-20 Initiated Barclays Underweight
Feb-25-20 Upgrade Guggenheim Neutral → Buy
Jan-30-20 Initiated RBC Capital Mkts Outperform
Nov-20-19 Resumed Guggenheim Neutral
Aug-07-19 Downgrade Guggenheim Buy → Neutral
Aug-07-19 Downgrade Raymond James Outperform → Mkt Perform
Jun-13-19 Initiated Mizuho Buy
Apr-12-19 Initiated Guggenheim Buy
Mar-27-19 Initiated Berenberg Buy
Mar-15-19 Initiated Raymond James Outperform
Sep-10-18 Resumed BTIG Research Buy
Mar-28-18 Resumed Leerink Partners Outperform
Mar-02-17 Initiated Instinet Neutral
Mar-02-17 Reiterated Wedbush Outperform
Oct-04-16 Initiated Piper Jaffray Overweight
Dec-22-15 Initiated Canaccord Genuity Buy
Aug-05-15 Reiterated MLV & Co Buy
Feb-12-15 Reiterated Oppenheimer Outperform
Jan-28-15 Reiterated MLV & Co Buy
Jul-11-14 Initiated Oppenheimer Outperform
View All

Xencor Inc Stock (XNCR) Latest News

pulisher
May 30, 2025

Xencor Inc (NASDAQ: XNCR) Jumps 2.45%: What Could Be On The Way Going Forward? - Stocksregister

May 30, 2025
pulisher
May 27, 2025

Xencor’s SWOT analysis: biotech stock faces pivotal year amid pipeline progress - Investing.com

May 27, 2025
pulisher
May 27, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $929,000 Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World

May 27, 2025
pulisher
May 26, 2025

Where are the Opportunities in (XNCR) - news.stocktradersdaily.com

May 26, 2025
pulisher
May 26, 2025

BNP Paribas Financial Markets Purchases 3,171 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World

May 26, 2025
pulisher
May 25, 2025

Xencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLC - Defense World

May 25, 2025
pulisher
May 25, 2025

Deutsche Bank AG Buys 20,128 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World

May 25, 2025
pulisher
May 23, 2025

Xencor, Inc. (XNCR) Stock Analysis: Exploring a Potential 266% Upside in Biotech Investments - DirectorsTalk Interviews

May 23, 2025
pulisher
May 23, 2025

Ameriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - Defense World

May 23, 2025
pulisher
May 19, 2025

Life Sciences Companies Have New Avenue to Challenge Patent Applications After Federal Court Ruling - JD Supra

May 19, 2025
pulisher
May 16, 2025

Xencor, Inc. (NASDAQ:XNCR) Position Boosted by Comerica Bank - Defense World

May 16, 2025
pulisher
May 16, 2025

Xencor Inc. Reports Revenue Growth Amidst Ongoing R&D Investments - TipRanks

May 16, 2025
pulisher
May 15, 2025

Northern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World

May 15, 2025
pulisher
May 14, 2025

Investor Network: Xencor, Inc. to Host Earnings Call - ACCESS Newswire

May 14, 2025
pulisher
May 14, 2025

Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

May 14, 2025
pulisher
May 13, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA) - The Globe and Mail

May 13, 2025
pulisher
May 12, 2025

Leerink Partnrs Has Bearish Forecast for Xencor Q2 Earnings - Defense World

May 12, 2025
pulisher
May 12, 2025

Wedbush Comments on Xencor’s Q2 Earnings (NASDAQ:XNCR) - Defense World

May 12, 2025
pulisher
May 12, 2025

Research Analysts Set Expectations for Xencor Q2 Earnings - Defense World

May 12, 2025
pulisher
May 11, 2025

JPMorgan cuts Xencor stock price target to $20, keeps overweight rating - Investing.com Nigeria

May 11, 2025
pulisher
May 11, 2025

Q4 Earnings Forecast for Xencor Issued By William Blair - Defense World

May 11, 2025
pulisher
May 11, 2025

What is Wedbush’s Estimate for Xencor Q4 Earnings? - Defense World

May 11, 2025
pulisher
May 10, 2025

Barclays Issues Pessimistic Forecast for Xencor (NASDAQ:XNCR) Stock Price - Defense World

May 10, 2025
pulisher
May 08, 2025

Xencor Inc earnings missed by $0.04, revenue topped estimates - Investing.com Nigeria

May 08, 2025
pulisher
May 08, 2025

Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Bar - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Barclays | XNCR Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

JPMorgan cuts Xencor stock price target to $20, keeps overweight rating By Investing.com - Investing.com South Africa

May 08, 2025
pulisher
May 08, 2025

Xencor Reports First Quarter 2025 Financial Results - BioSpace

May 08, 2025
pulisher
May 07, 2025

Xencor: Q1 Earnings Snapshot - MySA

May 07, 2025
pulisher
May 07, 2025

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 07, 2025
pulisher
May 05, 2025

(XNCR) Technical Data - news.stocktradersdaily.com

May 05, 2025
pulisher
May 02, 2025

Xencor (NASDAQ:XNCR) Earns Outperform Rating from Wedbush - Defense World

May 02, 2025
pulisher
May 01, 2025

Healthy Upside Potential: Xencor Inc (XNCR) - Sete News

May 01, 2025
pulisher
May 01, 2025

Xencor reports positive trial results for inflammatory bowel disease treatment - MSN

May 01, 2025
pulisher
May 01, 2025

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Wells Fargo & Company MN Raises Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Analyzing Xencor Inc (XNCR) After Recent Trading Activity - knoxdaily.com

Apr 30, 2025
pulisher
Apr 30, 2025

Trading Day Triumph: Xencor Inc (XNCR) Ends at 10.58, a -0.19 Surge/Plunge - DWinneX

Apr 30, 2025
pulisher
Apr 30, 2025

Is Xencor Inc (XNCR) a good investment opportunity? - uspostnews.com

Apr 30, 2025
pulisher
Apr 30, 2025

Xencor, Inc. to Host Earnings Call - ACCESS Newswire

Apr 30, 2025
pulisher
Apr 30, 2025

Xencor Announces Promising Phase 1 Study Results - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

Raymond James Financial Inc. Invests $2.33 Million in Xencor, Inc. (NASDAQ:XNCR) - Defense World

Apr 30, 2025
pulisher
Apr 29, 2025

Xencor (XNCR) Reports Promising Results and Advances XmAb942 Stu - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease - BioSpace

Apr 29, 2025
pulisher
Apr 29, 2025

Xencor posts trial data for bowel disease drug (XNCR:NASDAQ) - Seeking Alpha

Apr 29, 2025
pulisher
Apr 29, 2025

Xencor advances ulcerative colitis treatment into Phase 2b study - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Xencor (XNCR) Reports Promising Results and Advances XmAb942 Study | XNCR Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Xencor Inc Stock (XNCR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Cap:     |  Volume (24h):